Feiba VH (Anti-Inhibitor Coagulant Complex) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

FEIBA VH drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

CONTRAINDICATIONS

The use of FEIBA VH AICC is contraindicated in patients who are known to have a normal coagulation mechanism.

REFERENCES

1. Elsinger F.: Aktivierter Faktor VII in Prothrombinkomplex-Konzentraten. 23rd Annual Meeting of "Deutsche Arbeitsgemeinschaft für Blutgerinnungsforschung" (DAB), Heidelberg, 1979. F. K. Schattauer Verlag, Stuttgart-New York, 367, 1980.
2. Seligsohn U., østerud B., Rapaport S. I.: Coupled Amidolytic Assay for Factor VII: Its Use With a Clotting Assay to Determine the Activity State of Factor VII. Blood 52: 978, 1978.
3. Seligsohn U., Kasper C. K., østerud B., Rapaport S. I.: Activated Factor VII: Presence in Factor IX Concentrates and Persistence in the Circulation After Infusion. Blood 53: 828, 1979.
4. Mannucci P. M.: Personal communication
5. Sjamsoedin L. J. M., Heijnen L., Mauser-Bunschoten E. P., van Geijlswijk J. L., van Houwelingen H., van Asten P., Sixma J. J.: The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIII. The New Engl. J. of Med. 305: 717, 1981.
6. Roberts H. R.: Hemophiliacs with Inhibitors: Therapeutic Options. The New Engl. J. of Med. 305:757, 1981.
7. Hilgartner M. W., Knatterud G. AND THE FEIBA STUDY GROUP: The Use of Factor-Eight-Inhibitor-By-Passing-Activity (FEIBA IMMUNO) Product for Treatment of Bleeding Episodes in Hemophiliacs with Inhibitors. Blood 61: 36, 1983.
8. Thomas T., William. H., Williams Y., Hunt J.: FEIBA in Haemophiliacs with Factor VIII Inhibitor. Brit. Med. J. 1: 52, 1977.
9. Rolovic Z., Elezovic I., Oobrrenovic B.: Life-Threatening Bleeding Due to an Acquired Inhibitor to Factor XII- XI Successfully Treated with Feiba. Proceedings of Joint Meeting of the 18th Congress of the International Society of Hematology and 16th Congress of the International Society of Blood Transfusion, Montreal. Abstract 703, 1980.
10. Dormandy K.: Unpublished data.
11. Vinazzer H.: Personal communication.
12. Preston F. E.: A Review of Cases Treated with FEIBA in 1977/78. Presentation at the Second Workshop on Factor VIII Inhibitor Patients, Vienna, 1979.
13. Vermylen J., Sschetz J., Semeraro N., Mertens F., Verstraete M.: Evidence that 'Activated' Prothrombin Concentrates Enhance Platelet Coagulant Activity. Brit. J. Haematol. 38: 235, 1978.
14. Semeraro N., Vermylen J.: Evidence that Washed Human Platelets Possess Factor-X Activator Activity. Brit. J. Haematol. 36: 107, 1977.
15. Wensley R. T.: General Summary of the Use of FEIBA in Haemophiliacs with Inhibitors to FVIII. Presentation at the Second Workshop on Factor VIII Inhibitor Patients, Vienna, 1979.
16. Hilgartner M. W.: Personal communication.

To enroll in the confidential, Industry-wide Patient Notification System, call 1-888-UPDATE U (1-888-873-2838)

Baxter, FEIBA VH, FEIBA IMMUNO, PROTHROMPLEX IMMUNO and BAXJECT are trademarks of Baxter AG, Vienna, Austria; Baxter is a trademark of Baxter International, Inc., registered in the U.S. Patent and Trademark Office.

Baxter Healthcare Corporation © 2000 Baxter AG

Westlake Village, CA 91362 USA

All Rights Reserved

U.S. License No. 140

Revised 02/2003

U.S. Pat. Nos. 4,395,396 and 4,640,834

6205820EH18